key: cord-1017520-1qjwyxes authors: Lu, Hongzhou; Stratton, Charles W.; Tang, Yi‐Wei title: The Wuhan SARS‐CoV‐2—What's next for China date: 2020-03-18 journal: J Med Virol DOI: 10.1002/jmv.25738 sha: 60504d092319a1ef388ec72fdca830de7df0bd78 doc_id: 1017520 cord_uid: 1qjwyxes When an outbreak of pneumonia of unknown etiology occurred in Wuhan city, Hubei Province, China in December of 2019, the mystery1 was the nature of the causative agent. Because many of the patients had visited a fish and wild animal market, the possibility of a recurrence of severe acute respiratory syndrome (SARS) needed to be investigated2 . Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS)3 ? This article is protected by copyright. All rights reserved. When an outbreak of pneumonia of unknown etiology occurred in Wuhan City, Hubei Province, China, in December 2019, the mystery 1 was the nature of the causative agent. As many of the patients had visited a fish and wild animal market, the possibility of a recurrence of severe acute respiratory syndrome (SARS) needed to be investigated. 2 Finally, could this outbreak of pneumonia be caused by a novel coronavirus that was different from those causing SARS or Middle East respiratory syndrome (MERS) 3 ? Once this outbreak was recognized as a serious threat, a special team consisting of physicians, scientists, and epidemiologists began to investigate these possibilities. Within 9 days, SARS and MERS had been ruled out and a novel coronavirus had been isolated in Wuhan; this coronavirus is now officially named as the SARS-CoV-2 by the International Committee on Taxonomy of Viruses. The breadth and nature of the investigation that identified this novel SARS-CoV-2 is elaborately described by Zhu and colleagues in a recent publication in The New England Journal of Medicine. 4 Additional details subsequently have been published in several prestigious journals. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] This study is quite remarkable and praiseworthy. Given the subsequent spread to other parts of China as well as to other countries, the reasons for this spread should be examined. There are two such reasons that are noteworthy. The first is that the potential threat of these initial cases of pneumonia was not well-appreciated. The The question then is, "What's next for China?" As earlier suggested, there remains considerable work to be done. 1 This study includes many issues that can be determined in the short term as well as some that will require long-term solutions. Some of these issues are as follows. The timing of colonization, infection, and shedding need to be determined. For example, are infected persons first colonized? Do infected persons shed virus before they have clinical symptoms? Transmission characteristics need to be determined. Is infectious transmission limited to respiratory droplets or can the virus be transmitted by contact with an infected person? Efficient human-tohuman transmission is required for large-scale spread (ie, an epidemic or pandemic) of any emerging virus. Therefore, the basic reproductive ratio during this epidemic needs to be determined; the basic reproductive ratio is defined as the average number of secondary cases that an infected person produces during their entire infectious period in a susceptible and uninfected population. 15 The case-fatality rate needs to be accurately determined; the case-fatality rate of the SARS-CoV was around 11%. Some of these questions are already being addressed, 16, 17 but further work is needed. Often serology is required in such an epidemic to determine how many persons may have had clinically inapparent infections. Detection and identification methods that are accurate and can be performed in real time at the point of care or in the field need to be developed. 1 The exact relationship between the SARS-CoV-2 and animals (eg, bats) needs to be determined. 4, 18, 19 Although bats are suspected, the question of how the virus has moved from bats to the human host needs to be resolved. Does this transmission involve intermediate animal hosts as occurred with SARS-CoV and MERS-CoV? If the SARS-CoV-2 proves to have an animal sources, the continued presence of live animal markets in China must be seriously questioned. In the long term, the development of vaccines and antiviral therapy needs to be a higher priority than it has been since the SARS pandemic in 2002 to 2003; the lack of a SARS vaccine or SARS antiviral therapy suggests that such research has not been a priority. For example, Ampligen (poly I:poly C124) has been shown to inhibit SARS-CoV in a murine lung model, yet has not been further evaluated in humans. 20 Similarly, Remdesivir (GS-5734) has been shown to inhibit both epidemic and zoonotic coronaviruses. 21 It is likely that continued investigation of new antiviral agents with activity against coronaviruses in the absence of ongoing active epidemics would be enhanced by government incentives. Another issue in the long term that needs to be addressed is the potential of novel coronaviruses to spread within medical centers to health care workers as has happened with SARS-CoV and MERS-CoV. [22] [23] [24] Most medical centers, whether in China or in the United States, are not prepared for such a problem. For example, negative-pressure containment rooms with proper anterooms are either not found or found only in limited numbers in medical centers in the United States. 25 The recent epidemic in China caused by the SARS-CoV-2 is yet another example of emerging zoonotic viral diseases. 18 Like previous epidemics/pandemics caused by novel members of the coronavirus family, there are many lessons to be learned. Much work remains to be done before this latest coronavirus is fully understood and these lessons can be learned. Concept forming: HL and Y-WT. Writing: CWS. Revising and editing: HL and Y-WT. http://orcid.org/0000-0003-4888-6771 Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle SARS and MERS: recent insights into emerging coronaviruses Origin and evolution of pathogenic coronaviruses A novel coronavirus from patients with pneumonia in China Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan First case of 2019 novel coronavirus in the United States Clinical features of patients infected with 2019 novel coronavirus in Wuhan Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Transmission of 2019-nCoV infection from an asymptomatic contact in Germany Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan A pneumonia outbreak associated with a new coronavirus of probable bat origin Updates on Wuhan 2019 novel coronavirus epidemic Perspectives on the basic reproductive ratio Full spectrum of COVID-19 severity still being depicted Reconciling early-outbreak estimates of the basic reproduction number and its uncertainty: a new framework and applications to the novel coronavirus (2019-NCoV) outbreak. medRxiv Viral metagenomics revealed sendai virus and coronavirus infection of Malayan pangolins (Manis javanica) Emerging zoonotic viral diseases Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Hospital outbreak of Middle East respiratory syndrome coronavirus SARS in healthcare facilities A novel coronavirus emerging in China-key questions for impact assessment Designimg a biocontainment unit to care for patients with serious communicable deseases: a consensus statement